Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.69Last Year’s EPS
-1.31Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -10.48%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as resolving key manufacturing issues, demonstrating durable clinical benefits of INO-3107, and advancing the DMAb platform. However, challenges remain with pending FDA submissions and a decline in the cash position.Company Guidance
During the Inovio Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call, the company provided guidance on its strategic priorities for 2025. These include submitting a Biologics License Application (BLA) for INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), with the goal of starting the rolling submission process mid-year and completing it by the end of 2025. Inovio emphasized their progress in resolving manufacturing issues related to the CELLECTRA device and highlighted their ongoing efforts in advancing commercial plans for INO-3107, including market research and pricing strategy development. They also discussed the potential of their DNA-Encoded Monoclonal Antibodies (DMAb) technology, noting interim results from a Phase 1 trial showing durable antibody production over 72 weeks. Financially, Inovio reported a reduction in operational expenses, with a net loss of $107.3 million for 2024, and a cash runway projected to extend into the first quarter of 2026.Resolution of Manufacturing Issues
Inovio successfully resolved manufacturing issues with the single-use array component of the CELLECTRA device, allowing them to proceed with FDA-required device verification testing.
Advancements with INO-3107
INO-3107 showed durable clinical benefits with a 50% complete response rate in the second year and a greater than 75% reduction in surgeries across the patient population.
Progress on DNA-Encoded Monoclonal Antibodies (DMAb)
The Phase 1 trial showed that DMAbs for SARS-CoV-2 could be durably produced in humans at biologically relevant levels, demonstrating long-lasting in-vivo antibody production.
Financial Management
Inovio raised more than $72 million in gross proceeds and decreased operational spending by 22% from the previous year, estimating a cash runway into the first quarter of 2026.
---
INO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $2.10 | $1.96 | -6.67% |
| Nov 14, 2024 | $4.77 | $4.26 | -10.69% |
| Aug 08, 2024 | $8.71 | $8.44 | -3.10% |
| May 13, 2024 | $11.36 | $11.42 | +0.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inovio Pharmaceuticals (INO) report earnings?
Inovio Pharmaceuticals (INO) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Inovio Pharmaceuticals (INO) earnings time?
Inovio Pharmaceuticals (INO) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INO EPS forecast?
INO EPS forecast for the fiscal quarter 2025 (Q1) is -0.69.
---
